PARAMOUNT

NCT00789373 📎

Regimen

Experimental
pemetrexed continuation maintenance
Control
placebo

Population

Non-sq NSCLC, non-progressing after 4 cycles cis+pem induction

Key finding

PFS HR 0.62 (0.49-0.79); established continuation maintenance of pemetrexed post cis+pem induction

Source: PMID 22341744

Timeline

  • Enrollment start: 2008-11 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.186)
  • CSCO NSCLC 2025 ⚠️ OCR source